HILOmet PhyzioTypeTM System: High-Low Metabolic Risk for Neuro-Psychiatric and Cardio-Metabolic Drugs
Genomas has developed the HILOmet PhyzioType System to assist providers with DNA-based assessment tools to guide their neuro-psychiatric and cardio-metabolic drug choices for patients evidencing treatment resistance or drug intolerance. Our HILOmet tests have been developed in partnership with the Institute of Living (IOL, Hartford Hospital, Connecticut), a major research-based psychiatric hospital, recognized as a Top-20 center by US News & World Report. IOL enjoys a national reputation for excellence, comprehensive patient care, research and education in the fields of behavioral, psychiatric and addiction disorders, with more than 185 years of continuous service.
Genomas currently offers its HILOmet PhyzioType System for DNA-Guided neuro-psychiatric and cardio-metabolic drug management. Physicians refer patients for evaluation of innate drug metabolism reserve and metabolic risk for 250 medications: 130 neuro-psychiatric drugs (antidepressants, neuroleptics, anticonvulsants, anxiolytics, stimulants, analgesics, hypnotics) and 120 cardio-metabolic drugs (to treat hypertension, diabetes, angina, thrombosis, GERD, ED, asthma).
The HILOmet PhyzioType System provides, through 3 individually assayed tests, high-resolution combinatorial genotyping results of a total of 37 variants in genes CYP2D6, CYP2C9 and CYP2C19 (20, 7, and 10 alleles, respectively). The respective CYP2D6, CYP2C9, and CYP2C19 isoenzymes encoded by these genes are critical for metabolism of neuro-psychiatric and cardio-metabolic drugs, and their variable biochemical properties substantially alter individual patient drug response. Based on our clinical studies and case reports, the HILOmet PhyzioType System offers interpretative guidance to assess the functional status of the patient’s drug metabolism in order to establish functionalities and deficiencies. Physicians can then make prescribing decisions based on knowledge of those metabolic capabilities and deficits. HILOmet testing is supported for prescription management by the Personalized Health Portal (PHP), a proprietary medical informatics and graphical web interface for DNA-guided drug prescription.
HILOmet tests are performed at the Laboratory of Personalized Health (LPH) at Hartford Hospital. LPH is a high-complexity clinical DNA testing center licensed by the Connecticut Department of Public Health (License CL-0644), the New York Department of Health (Permanent Facility Identifier 8648), the California Department of Public Health (Lab ID # COS 00800405), the Florida Agency for Health Care Administration (License # 800026696), Rhode Island Department of Health (License # LCO-00591), and certified by the Centers for Medicare and Medicaid Services (ID # 07D1036625) under CLIA (Clinical Laboratory Improvement Amendments). With nearly 5000 patients referred by 500 clinicians, LPH has achieved highly streamlined operations, including test requisition, analysis, reporting, and reimbursement. The HILOmet PhyzioType System has been extensively published and presented consecutively at the annual meetings of the American Psychiatric Association over 2007-2014. A patent on the HILOmet PhyzioType product is pending.
Through HILOmet tests, the innate metabolic capacity of the patient can be predicted and diagnosed simply from a blood sample or buccal swab. Patients intolerant to these drugs or refractory to treatment can be benchmarked for their drug metabolism function and innate reserve by HILOmet combinatorial genotyping. Therapy can be directed to drugs that pose the least metabolic risk, whose primary metabolic pathway is functional, while avoiding drugs with the most metabolic risk, whose primary metabolic pathways are ultra-rapid, deficient or null. The guidance provided by the HILOmet PhyzioType tests for an individual patient markedly improves the safety and efficacy of neuro-psychiatric and cardio-metabolic therapy. For information on ordering the HILOmet tests please click here.